Chantix
Product Images NDC 69189-0492

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Chantix (NDC 69189-0492). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Varenicline 0.5 mg Tablet (6918904921)

Packaging label for CHANTIX 0.5 mg tablet containing varenicline. The label indicates Pfizer as the manufacturer, with batch and expiration details including lot numbers and an expiration date of 01/21/2017. It is labeled by Avera McKennan Hospital in Sioux Falls, SD, and displays the NDC 69189-0492.*

FDA Label Image

Chemical Structure (Chantix 01)

Chemical structure of the active ingredient in CHANTIX, showing a bicyclic system with nitrogen atoms and a substituted carboxylate group, indicating the detailed molecular arrangement.*

FDA Label Image

Figure 1 (Chantix 02)

A bar chart comparing the results of CHANTIX at 10 mg BID and other formulations against placebo across five studies. Each study shows percentage-based outcomes with error bars for CHANTIX 10 mg BID compared to placebo or other treatments like CHANTIX flexible and Bupropion SR 150 mg BID. The vertical axis represents a percentage scale from 0% to 60%.*

FDA Label Image

Figure 2 (Chantix 03)

A bar graph depicting results from five studies comparing CHANTIX 0.5 mg BID, CHANTIX 10 mg BID, and CHANTIX Flexible dosing against placebo, and in some studies against Bupropion SR 150 mg BID. The vertical axis shows percentages from 0% to 35%, with error bars indicating variability in each treatment group.*

FDA Label Image

Figure 3 (Chantix 04)

A line graph comparing the percentage of continuous abstinent individuals over nontreatment follow-up weeks between CHANTIX 1.0 mg BID and placebo groups. The x-axis represents follow-up duration in weeks, and the y-axis shows the percentage of continuous abstinence. CHANTIX maintains higher abstinence rates compared to placebo throughout the follow-up period.*

FDA Label Image

Logo (Chantix 05)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.